Society of Family Planning Clinical Recommendation: Contraceptive considerations for individuals with cancer and cancer survivors part 3 - Skin, blood, gastrointestinal, liver, lung, central nervous system, and other cancers: Joint with the Society of Gynecologic Oncology

Abstract

This Clinical Recommendation provides evidence-informed, person-centered, and equity-driven recommendations to facilitate the management of and access to contraception care for individuals who are diagnosed with, being actively treated for, or who have previously been treated for skin, blood, gastrointestinal, liver, lung, central nervous system, and other cancers. For individuals with a history of nonmelanoma skin cancers, we recommend clinicians provide access to all available contraceptive methods utilizing a person-centered approach (GRADE 1B). Based on expert opinion, for individuals with a history of melanoma who are considering hormonal contraception, we suggest shared decision-making with the individual and their oncologist (GRADE 2C). For individuals with a history of myeloproliferative neoplasms, lymphatic or hematopoietic cancer, and hematopoietic stem cell transplantation, we recommend clinicians provide access to all contraceptive methods (GRADE 1B); we suggest shared decision-making in those with follicular lymphoma subtype of non-Hodgkin lymphoma who are considering hormonal contraception (GRADE 2C). For individuals with a history of colorectal, pancreatic, esophageal, and gastric cancer, we recommend clinicians provide access to all available contraceptive methods (GRADE 1C). We recommend clinicians provide access to all available contraceptive methods in individuals with a history of primary hepatocellular carcinoma with normal liver function (GRADE 1C); with severely altered liver function, we recommend nonhormonal and progestin-only contraceptives as first-line contraceptive methods (GRADE 1B). For individuals with a history of glioma, we recommend clinicians provide access to all available contraceptives (GRADE 1B). For individuals with a history of meningioma who request hormonal contraception, we recommend shared decision-making with the individual and their oncologist (GRADE 2B). We recommend clinicians provide access to all available contraceptive options for individuals with a history of or active bladder, kidney, thyroid, head and neck squamous cell, and soft tissue sarcomas (GRADE 1B). This document is part 3 of a three-part series that updates the Society of Family Planning's 2012 Cancer and contraception clinical guidance. It builds upon the considerations outlined in the Society of Family Planning Committee Statement: Contraceptive considerations for individuals with cancer and cancer survivors part 1 - Key considerations for clinical care and parallels recommendations outlined in the Society of Family Planning Clinical Recommendation: Contraceptive considerations for individuals with cancer and cancer survivors part 2 - Breast, ovarian, uterine, and cervical cancer. Readers are encouraged to review parts 1 and 2 for this additional context.

Keywords: Blood; Cancer; Contraception; Gastrointestinal; Hormone; Survivor.